Charles Schwab Investment Management Inc. Raises Stock Holdings in LifeStance Health Group, Inc. $LFST

Key Points

• Charles Schwab Investment Management Inc. increased its stake in LifeStance Health Group by 4.4%, owning 1,162,136 shares worth approximately $7.74 million after purchasing an additional 48,637 shares.
• LifeStance Health Group reported revenues of $345.31 million in its latest quarter, exceeding analysts' expectations, with a 10.6% increase compared to the previous year.
• Recent analyst reports indicate a consensus rating of "Moderate Buy" for LifeStance, with an average price target set at $8.50, reflecting positive sentiment towards the company's future prospects.

Charles Schwab Investment Management Inc. raised its stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 4.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,162,136 shares of the company's stock after acquiring an additional 48,637 shares during the period. Charles Schwab Investment Management Inc. owned about 0.30% of LifeStance Health Group worth $7,740,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. DekaBank Deutsche Girozentrale bought a new position in LifeStance Health Group during the 1st quarter valued at $31,000. Xponance Inc. purchased a new stake in LifeStance Health Group in the 1st quarter worth about $69,000. Ameriprise Financial Inc. bought a new stake in shares of LifeStance Health Group during the 4th quarter valued at about $87,000. Kapitalo Investimentos Ltda bought a new stake in shares of LifeStance Health Group during the 1st quarter valued at about $87,000. Finally, Forum Financial Management LP bought a new stake in shares of LifeStance Health Group during the 4th quarter valued at about $110,000. 85.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on LFST shares. BTIG Research started coverage on LifeStance Health Group in a research report on Friday, July 25th. They set a "buy" rating and a $8.00 price target for the company. Wall Street Zen upgraded LifeStance Health Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, UBS Group lifted their price target on LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.

Insiders Place Their Bets

In related news, Director Darren M. Black sold 8,407,643 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the sale, the director directly owned 33,524,715 shares of the company's stock, valued at $169,970,305.05. This represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ujjwal Ramtekkar sold 16,000 shares of the company's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $5.94, for a total value of $95,040.00. Following the completion of the sale, the insider directly owned 113,435 shares in the company, valued at approximately $673,803.90. The trade was a 12.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,423,643 shares of company stock worth $103,561,790 in the last ninety days. Insiders own 6.60% of the company's stock.

LifeStance Health Group Stock Performance

LFST stock remained flat at $5.48 during midday trading on Monday. The company's stock had a trading volume of 2,067,678 shares, compared to its average volume of 3,220,483. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $2.13 billion, a PE ratio of -109.60 and a beta of 1.17. The firm has a 50 day moving average price of $4.73 and a 200 day moving average price of $5.87. LifeStance Health Group, Inc. has a 12-month low of $3.74 and a 12-month high of $8.61.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $345.31 million during the quarter, compared to the consensus estimate of $345.05 million. LifeStance Health Group had a negative return on equity of 1.11% and a negative net margin of 1.23%.The firm's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.06) earnings per share. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.